- A 6.9% increase in the overall number of samples analyzed: 322,050 in 2017 to 344,177 in 2018.
- A slight decrease in the total percentage of Adverse Analytical Findings (AAFs): 1.43% in 2017 (4,596 AAFs from 322,050 samples) to 1.42% in 2018 (4,896 AAFs from 344,177 samples).
- About 60% of WADA-accredited Laboratories saw an increase in the total number of samples recorded.
- An increase in the total number and percentage of non-Athlete Biological Passport (ABP) blood samples analyzed: 8.62% in 2017 (27,759 of 322,050) to 9.11% in 2018 (31,351 of 344,177).
- An increase of 7% in the number of ABP blood samples tested: 29,130 in 2017 to 31,261 in 2018.
The World Anti-Doping Agency (WADA) today publishes its (2018 Report), which summarizes the results of all the samples WADA-accredited Laboratories analyzed and reported in WADA’s Anti-Doping Administration and Management System (ADAMS) in 2018.
This is the fourth set of global testing results since the 2015 (Code) came into effect. The 2018 Report – which includes an and sub-reports by Laboratory, Sport, Testing Authority and ABP Blood Analysis – includes in- and out-of-competition urine samples; blood and ABP blood data; and, the resulting AAFs and Atypical Findings (ATFs).
WADA Director General Olivier Niggli said: “The 2018 Testing Figures Report offers a comprehensive reflection of all doping control samples analyzed and reported by all WADA-accredited and -approved Laboratories around the world in 2018.
“The Report provides a wealth of information to the Anti-Doping Organizations (ADOs) and allows them to observe patterns of doping control programs by sport, organization, substance and laboratory. ADOs can then use this valuable intelligence to adapt their anti-doping strategies and better target test their athletes, thus helping to protect clean athletes and the integrity of sport.”
To help with the interpretation of the 2018 Report, we provide a comprehensive . Of particular importance, please note that:
- One single result does not necessarily correspond to one athlete. Results may correspond with multiple findings regarding the same athlete or measurements performed on the same athlete, such as in the case of longitudinal studies of testosterone.
- The number of AAFs in the Report may not correspond with the number of Anti-Doping Rule Violations (ADRVs) reported by ADOs. This is because all results are subject to a results management process conducted by ADOs, which includes matching results with Therapeutic Use Exemptions (TUEs), and longitudinal studies which can result in no case to answer or no sanction.
- As usual, this Report does not illustrate statistics on ADRVs, which are reported via a separate ADRV Report – the 2018 version of which will be released in 2020. The ADRV Report reveals analytical and non-analytical cases and the outcomes of results management, which is a process that can take a long time given that it may include investigations, appeals, etc.